Evidence map›Paper›PMID 27563825›Full record

ArticleOncotarget2016

Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis.

Kiyoko Takane, Keisuke Matsusaka, Satoshi Ota, Masaki Fukuyo, Yao Yue, Motoi Nishimura, Eiji Sakai, Kazuyuki Matsushita, Hideaki Miyauchi, Hiroyuki Aburatani and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Kiyoko TakaneDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Keisuke MatsusakaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Satoshi OtaDepartment of Pathology, Chiba University Hospital, Chiba, Japan.
Masaki FukuyoDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yao YueDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
Motoi NishimuraDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
Eiji SakaiDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kazuyuki MatsushitaDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hideaki MiyauchiDepartment of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroyuki AburataniGenome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Yukio NakataniDepartment of Pathology, Chiba University Hospital, Chiba, Japan.
Tadatoshi TakayamaDepartment of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.
Hisahiro MatsubaraDepartment of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kiwamu AkagiDivision of Molecular Diagnosis, Saitama Cancer Center, Saitama, Japan.
Atsushi KanedaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Chiba University · JPChiba University Hospital · JPThe University of Tokyo · JPNihon University · JPSaitama Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While sporadic colorectal cancer (CRC) is classified into several molecular subtypes, stratification of familial colorectal tumors is yet to be well investigated. We previously established two groups of methylation markers through genome-wide DNA methylation analysis, which classified sporadic CRC and adenoma into three distinct subgroups: high-, intermediate-, and low-methylation epigenotypes. Here, we investigated familial adenomatous polyposis (FAP), through quantitative methylation analysis of 127 samples (16 cancers, 96 adenomas, and 15 benign mucosa from 14 patients with FAP) using six Group-1 and 14 Group-2 methylation markers, APC, BRAF, and KRAS mutation analysis, and CTNNB1 and TP53 immunohistochemical analysis. All the 14 patients presented with APC germline mutation. Three were from the same family and presented the same APC mutation. FAP tumors lacked BRAF-mutation(+) high-methylation epigenotype and were classified into two methylation epigenotypes. While 24 of 112 tumor samples showed intermediate-methylation epigenotype significantly correlating with KRAS-mutation(+) (P=3×10-4), 88 tumor samples showed low-methylation epigenotype correlating with the absence of KRAS- and BRAF-mutations. Similar to sporadic CRC, CTNNB1 was frequently activated at the adenoma stage, and TP53 mutation occurred during cancer development from adenoma. Whereas some patients showed a single epigenotype in all tumors throughout the colon, tumors with two distinct epigenotypes developed within a family with the same APC mutation or even within one patient. Methylation accumulation significantly correlated with proximal location and older age. These results indicate that there are at least two distinct molecular subtypes of FAP tumors, resembling sporadic CRC and independent from the APC germline mutation status.

Indexed as

DNA MethylationEpigenesis, GeneticAdenomatous Polyposis ColiAdenomatous Polyposis Coli ProteinAdolescentAdultAgedAge Factorsbeta CateninBiomarkers, TumorCluster AnalysisDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseGerm-Line MutationHumansAdenomatous Polyposis Coli ProteinAPC protein, humanbeta CateninBiomarkers, TumorBRAF protein, humanCTNNB1 protein, humanKRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53CIMPcolorectal cancerDNA methylationfamilial adenomatous polyposis (FAP)KRAS

Identifiers

PMID27563825
PMCPMC5356641
OpenAlexW2518530926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.